CASI Pharmaceuticals, Inc.
CASINASDAQHealthcare
$0.15
+$0.00(+3.08%)
Market Cap$2331664
P/E Ratio—
52W High$3.09
52W Low$0.135
CASI Pharmaceuticals, Inc. (CASI) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CASI · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $28.54M | $33.88M | $43.11M | $30.17M | $15.14M |
| Cost of Revenue | $17.39M | $13.83M | $15.83M | $12.56M | $9.51M |
| Gross Profit | $11.15M | $20.05M | $27.28M | $17.61M | $5.63M |
| Gross Margin %(computed) | 39.06% | 59.19% | 63.28% | 58.38% | 37.20% |
| Operating Expenses | |||||
| R&D Expenses | $8.92M | $9.86M | $16.00M | $14.42M | $11.47M |
| G&A Expenses | $23.58M | $25.39M | $23.45M | $23.70M | $19.66M |
| Total Operating Expenses | $50.77M | $45.13M | $53.77M | $59.13M | $58.41M |
| Operating Income | ($39.62M) | ($25.08M) | ($26.49M) | ($41.52M) | ($52.78M) |
| Operating Margin %(computed) | -138.84% | -74.03% | -61.45% | -137.62% | -348.60% |
| Interest Income | $0.54M | $0.61M | $0.19M | $0.32M | $0.87M |
| Interest Expense | $0.87M | $0.00M | $0.06M | $0.00M | $0.00M |
| Income Before Tax | ($38.07M) | ($26.29M) | ($38.28M) | ($35.84M) | ($47.51M) |
| Income Tax Expense | $1.19M | ($0.08M) | $1.98M | $0.00M | $0.00M |
| Net Income | ($39.26M) | ($26.94M) | ($41.01M) | ($36.65M) | ($48.29M) |
| Net Margin %(computed) | -137.57% | -79.51% | -95.14% | -121.50% | -318.92% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.56 | $-2.02 | $-3.01 | $-2.69 | $-4.37 |
| Wtd Avg Shares | 15.34M | 13.36M | 13.65M | 13.61M | 11.05M |
| EBITDA | ($34.87M) | ($21.54M) | ($24.07M) | ($33.40M) | ($31.35M) |
| EBITDA Margin %(computed) | -122.18% | -63.58% | -55.84% | -110.72% | -207.08% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more CASI Pharmaceuticals, Inc. data
About CASI Pharmaceuticals, Inc. (CASI) Income Statement
CASI Pharmaceuticals, Inc. (CASI) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, CASI reported revenue of $0.03B, gross profit of $0.01B (gross margin 39.06%), and net income of ($0.04B) — a net profit margin of -137.57%.
Frequently asked questions
CASI · 4 questionsCASI Pharmaceuticals, Inc. (CASI) reported revenue of $0.03B for 2024, down 15.8% year-over-year.
CASI revenueCASI salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09